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Background: To evaluate the efﬁcacy of holmium laser enucleation of the prostate (HoLEP) followed by
high-intensity focused ultrasound (HIFU) for patients with huge prostate adenoma and localized prostate
cancer (CaP) and compare the morbidity and efﬁcacy results with those observed in a similar population
treated only with HIFU for a follow-up period of up to 5 years.
Methods: The present retrospective study included 30 CaP patients who underwent HIFU alone and 10
patients who underwent HoLEP followed by HIFU. Selection criteria for this study were no previous
treatment for CaP, aged 60 years or older, cT1c-T2N0M0, prostate volume of 30 mL or more, and a follow-
up period of 5 years or more. Prostate-speciﬁc antigen (PSA) biochemical recurrence-free survival (RFS)
rates and functional outcomes including complications and uroﬂowmetry after HIFU were compared
between the HIFU monotherapy and HoLEP þ HIFU groups.
Results: The enrolled patients had a mean age of 70.3 years and 68.8 years in the HIFU monotherapy and
HoLEP þ HIFU groups, respectively. The 5-year PSA biochemical RFS rates of the two groups were similar
(HIFU monotherapy group: 57.2%; HoLEP þ HIFU group: 67.5%). The duration of indwelling urethral
catheter after HIFU signiﬁcantly decreased in the HoLEP þ HIFU group compared with the HIFU mon-
otherapy group (15.5 ± 2.7 days vs. 27.5 ± 2.3 days, P¼ 0.022). In terms of functional outcomes, patients
who received HoLEP þ HIFU had signiﬁcantly higher maximum (12 months: P¼ 0.015, 36 months:
P¼ 0.014) and average (36 months: P¼ 0.002, 60 months: P¼ 0.047) ﬂow rates than those who received
HIFU monotherapy. The frequency of urethral stricture (13.3% vs. 0%), symptomatic urinary tract infection
(10.0% vs. 0%), and bladder stone and urethrorectal ﬁstula (3.3% vs. 0%) tended to be higher in the HIFU
monotherapy group as compared with the HoLEP þ HIFU group.
Conclusion: The HoLEP þ HIFU treatment decreases urinary catheterization time and improves post-
treatment urinary status without additional morbidity.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although radical prostatectomy and radiotherapy are consid-
ered the gold standard treatment for localized prostate cancer
(CaP), organ-sparing alternatives are becoming increasingly popu-
lar among patients with low-stage CaP.1 High-intensity focused
ultrasound (HIFU) is a new modality that can be used for local tu-
mor ablation therapy.2 The most critical disadvantage of HIFU is the
long-term indwelling urethral catheterization. When utilizing HIFUTeikyo University School of
Japan.
o).
ciﬁc Prostate Society, Published bwithout transurethral resection of the prostate (TURP), obstructed
patients have a signiﬁcant risk of prolonged (almost 6 weeks) uri-
nary retention.3 Immediate post-HIFU retention results from the
edema in relation to the tissue coagulation. After edema resorption,
urinary retention may be prolonged by the elimination of necrotic
debris. Several groups have attempted to utilize TURP to reduce the
burden on patients.3,4
At least in Japan, however, the standard technique for benign
prostate hyperplasia (BPH)/lower urinary tract symptom in recent
years has been holmium laser enucleation of the prostate (HoLEP).5
The functional beneﬁts of HoLEP are well-established. Because
HoLEP is easy to perform and is associated with a low complication
rate and short hospital stay, this effective surgical alternative toy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient characteristics
HIFU HoLEP þ HIFU P
N 30 10
Age (y) 70.3 ± 5.8 68.8 ± 23.4 0.578
Prostate volume (mL) 38.9 (35.5e46.3) 36.7 (31.1e42.4) 0.414
Period between
HoLEP and HIFU (d)
d 96.5 (89.8e103) d
HIFU operation time (min) 176 (110e207) 108 (101.5e109.8) 0.002
HIFU ablation time (min) 104.5 (69.3e130.8) 71.5 (70e75) 0.030
T classiﬁcation 0.376
cT1a 24 (80.0) 6 (60.0)
cT2a 4 (13.3) 2 (20.0)
cT2b 2 (6.7) 2 (20.0)
Gleason score 0.516
 3 þ 3 17 (56.7) 5 (50.0)
3 þ 4 5 (16.7) 3 (30.0)
4 þ 3 4 (13.3) 0 (0.0)
 4 þ 4 4 (13.3) 2 (20.0)
D'Amico et al's9
risk stratiﬁcation
0.141
Low 13 (43.3) 1 (10.0)
Intermediate 11 (36.7) 5 (50.0)
High 6 (20.0) 4 (40.0)
Initial PSA (ng/mL) 7.05 (5.90e12.49) 8.14 (5.36e21.37) 0.062
Data are presented as n (%) or mean ± SD, or mean (interquartile range).
HIFU, high-intensity focused ultrasound; HoLEP, holmium laser enucleation of the
prostate; PSA, prostate-speciﬁc antigen.
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relegated to the past.6 Moreover, even in combination with TURP,
8% of cases needed additional deobstruction procedure. We
therefore evaluated the efﬁcacy of HoLEP followed by HIFU for
patients with huge prostate adenoma and localized CaP and
compared themorbidity and efﬁcacy results with those observed in
a similar population treated only with HIFU for a follow-up period
of up to 5 years.
2. Materials and methods
2.1. Patients
We included patients with huge prostate adenoma and localized
CaP who underwent HoLEP followed by a single HIFU session from
November 2006 to April 2010 in this retrospective study. The se-
lection criteria for this study were age older than 60 years, cT1c-
T2N0M0, prostate volume of  30 mL, and follow-up periods of >
5 years. All patients were either unsuitable for radical prostatec-
tomy because of comorbidities or preferred HIFU treatment over
surgery or radiation therapy. All patients provided written
informed consent before entering the study. We selected patients
who underwent only a single session of HIFU monotherapy with a
prostate volume of over 30 mL as the control group. All patients in
both groups underwent a prostate biopsy including more than 14
cores. None of the patients who received androgen-deprivation
therapy before the HoLEP and HIFU was selected for treatment
and analysis.
2.2. HoLEP treatment
A 26-Fr Storz endoscope (KARL STORZ Inc., Tuttlingen, Ger-
many) with a continuous saline irrigation system equipped with a
device for ﬁxing the 550-mm laser ﬁber was used. A pulsed, high-
powered holmium neodymium:yttriumealuminum garnet laser
beam was generated by Versa Pulse Select 80 (Lumenis Inc., San
Jose, CA, USA). Transurethral mechanical morcellation was
performed.
2.3. HIFU treatment
All patients received HIFU treatment using the Sonablate® under
general anesthesia. Patients were placed in the supine position
with their legs apart to receive transrectal HIFU. Treatment was
performed using a transrectal probe including a 4-MHz piezoelec-
tric treatment transducer and a 4-MHz ultrasound imaging probe.
Contiguous HIFU shots were delivered 1.8 mm apart with a 4-
second shot duration and a 12-second interval between shots.
Treatment volume was determined by the urologist, who used a
longitudinal and transverse ultrasound imaging system. The pa-
tients were discharged the day following HIFU.
2.4. Follow-up
During the follow-up period, prostate-speciﬁc antigen (PSA)
was measured every 6 months for 5 years. Serum PSA was
analyzed with the chemiluminescent enzyme-linked immuno-
assay (normal range  4 ng/mL). We used two PSA biochemical
failure deﬁnitions: (1) the ASTRO II “Phoenix” biochemical failure-
free survival 2006 consensus deﬁnition of a PSA increase of 2 ng/
mL above the nadir PSA7 and (2) the Stuttgart deﬁnition of a PSA
increase of 1.2 ng/mL above the nadir PSA.8 Distributions of PSA
biochemical recurrence-free survival (RFS) rates were calculated
according to the KaplaneMeier curves, and the log-rank test were
used to determine the differences between the curves. The riskclassiﬁcation was based on that reported by D'Amico et al.9 “Low
risk” was deﬁned as clinical T stages T1c and T2a, Gleason score of
 6, and PSA < 10 ng/mL. Conversely, patients with clinical stage
T2c disease or a PSA > 20 ng/mL or a biopsy Gleason score of  8
were identiﬁed to be in a “high-risk group.” The remaining pa-
tients with PSA levels > 10 ng/mL but < 20 ng/mL, a biopsy Gleason
score of 7, or clinical stage T2b were identiﬁed to be at “interme-
diate risk.”
We recorded medical information, including adverse events
exceeding Grade 3, according to The National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE), version
4.0. Uroﬂowmetry was performed at 1 year, 3 years, and 5 years
after HIFU.2.5. Statistical analysis
Paired t test and Fisher's exact test were used to compare
quantitative and categorical variables, respectively. All P values
< 0.05 reﬂected statistically signiﬁcant differences.3. Results
3.1. Patient characteristics
Table 1 summarizes the baseline clinical characteristics of the
patients. We included 30 patients in the HIFU monotherapy group
and 10 patients in the HoLEP þ HIFU group. There were no signif-
icant differences in age, prostate volume, initial PSA, clinical T stage,
Gleason score, or D'Amico et al's9 risk stratiﬁcation between
groups. Although we consider that low-risk disease is the best
candidate for HIFU, because of the retrospective nature of this
study, we were compelled to include patients with intermediate or
high risk as well. These patients had a preference for HIFU because
they were older than 80 years and had severe comorbidities
including thrombosis, which required continuous treatment with
antiplatelet drugs. The HIFU operation and ablation time in the
HoLEP þ HIFU group were signiﬁcantly shorter than in the HIFU
Horiuchi et al / HoLEP and HIFU for CaP 51monotherapy group (HIFU operation time: P¼ 0.002; HIFU ablation
time: P¼ 0.030, Table 1). The mean duration between HoLEP and
HIFU in the HoLEP þ HIFU group was 96.5 days.
3.2. Oncological results
Pathological ﬁndings of all HoLEP specimens showed benign
disease. Compared with the HIFU monotherapy group, PSA levels
drastically decreased signiﬁcantly in the HoLEP þ HIFU group after
HIFU (at 6 months, P¼ 0.009; at 12 months, P¼ 0.030; at 24
months, P¼ 0.046; at 36 months, P¼ 0.040; and at 60 months,
P¼ 0.027; Fig. 1). Although there were no signiﬁcant differences in
time to PSA nadir (P¼ 0.171), PSA nadir in the HoLEP þ HIFU group
(median, 0.003 ng/mL) was signiﬁcantly lower than in the HIFU
monotherapy group (median, 0.014 ng/mL, P¼ 0.033). The 5-year
PSA biochemical RFS rates according to the Phoenix ASTRO deﬁ-
nition in the HIFU monotherapy and HoLEP þ HIFU groups were
57.2% and 67.5%, respectively (Fig. 2A). The 5-year PSA biochemical
RFS rates according to the Stuttgart deﬁnition in the HIFU mono-
therapy and HoLEP þ HIFU groups were 48.8% and 67.5%, respec-
tively (Fig. 2B). No signiﬁcant differences in the 5-year PSA
biochemical RFS rates between both groups were noted using the
Phoenix ASTRO (P¼ 0.618) or the Stuttgart deﬁnition (P¼ 0.297).
There were no signiﬁcant differences in PSA biochemical RFS rates
between the HIFUmonotherapy and HoLEPþHIFU groups (Table 2)
in any of the D'Amico et al9 risk groups. In the HIFU monotherapy
group, ﬁve patients progressed to require further treatment. By
contrast, no patient in the HoLEP þ HIFU group needed any adju-
vant treatment. At the time this study was undertaken, no patient
had lymphatic or distant metastasis.
3.3. Functional results
No patient in either group complained of more than Grade 3
incontinence (as deﬁned by CTCAE version 4.0). The duration of
indwelling urethral catheter after HIFU signiﬁcantly decreased in
the HoLEP þ HIFU group compared with the HIFU monotherapy
group (15.5 ± 2.7 days vs. 27.5 ± 2.3 days, P¼ 0.022; Table 3). In
terms of uroﬂowmetry, maximum (Qmax) (12 months, P¼ 0.015; 36
months, P¼ 0.014), and average ﬂow rates (Qave; 36 months,
P¼ 0.002; 60 months, P¼ 0.047) in the HoLEP þ HIFU group were
signiﬁcantly higher than those in the HIFU monotherapy group
(Fig. 3). The frequency of urethral stricture, symptomatic urinary
tract infection, and bladder stone and urethrorectal ﬁstula tendedFig. 1. Comparison of PSA levels after HIFU between the HIFU and HoLEP þ HIFU groups. PSA
the HIFU monotherapy group. a) P < 0.05. HIFU, high-intensity focused ultrasound; HoLEP,to be higher in the HIFU monotherapy group as compared with the
HoLEPþ HIFU group, although statistically nonsigniﬁcant (Table 3).
Transient urinary retention due to urethral stricture was noted in
four patients (13.3%) in the HIFU monotherapy group who received
TURP.4. Discussion
Although the number of patients included in this study was very
small, we could show that HoLEP prior to HIFU can decrease
adverse events for patients with HIFU. One of the main drawbacks
of HIFU is the need for prolonged indwelling urethral catheteriza-
tion following HIFU. Because of HIFU-related edema, patients un-
derwent urethral catheterization for 2e3 weeks following the
procedure.4 Generally speaking, this catheterization may be a
frequent cause of urethral stricture, urinary tract infection, bladder
stone, and similar complications. Considering that previously re-
ported HIFU caused high incidences of urinary stricture, many HIFU
specialists have reported new concepts and methodologies to
decrease the duration of indwelling catheterization.3 TURP is now
becoming the standard procedure. The combination of HIFU and
TURP reduces postoperative sloughing of urethral tissue, thereby
achieving improvement in urination after HIFU.10 Many notable
groups have performed TURP as a ﬁxed protocol.11,12 It may be
performed before or immediately after the HIFU procedure.
The time when TURP was the gold standard for BPH is now long
past. As technology has advanced, BPH treatment has expanded
past TURP to HoLEP, which enables the immediate relief of bladder
outlet obstruction and produces an excellent outcome in terms of
feasibility, safety, and efﬁcacy.5 The favorable hemostatic charac-
teristics of the holmium procedure have signiﬁcantly shortened
median catheterization time and median postoperative hospital
stay.6
We could show that the indwelling urethral catheterization
period after HIFU was signiﬁcantly decreased in the HoLEP þ HIFU
group compared with the HIFU monotherapy group in this study.
Although not statistically signiﬁcant, no patient with HoLEPþ HIFU
experienced urinary retention due to urethral stricture in the
HoLEP þ HIFU group compared with four cases (13.3%) in the HIFU
monotherapy group. Previous reports indicated that the frequency
of urethral stricture was 4e24.6% after HIFU.10,13e15 Therefore, it is
safe to say that HoLEP followed by HIFU could decrease the periods
of indwelling urethral catheterization after HIFU, and consequently
decrease the frequency of urethral stricture. In addition, in manylevels after HIFU in the HoLEP þ HIFU group were generally signiﬁcantly lower than in
holmium laser enucleation of the prostate; PSA, prostate-speciﬁc antigen.
Fig. 2. KaplaneMeier PSA biochemical RFS curves after HIFU. (A) KaplaneMeier PSA biochemical RFS curves according to the Phoenix ASTRO deﬁnition. Using the Phoenix ASTRO
deﬁnition, there were no signiﬁcant differences in PSA biochemical RFS rates between groups (5-year RFS rate: HIFU group, 57.2%; HoLEP þ HIFU group, 67.5%; P¼ 0.618). (B)
KaplaneMeier PSA biochemical RFS curves according to the Stuttgart deﬁnition. Using the Stuttgart deﬁnition, there were no signiﬁcant differences in PSA biochemical RFS rates
between groups (5-year RFS rate: HIFU group, 48.8%; HoLEP þ HIFU group, 67.5%; P¼ 0.297). HIFU, high-intensity focused ultrasound; HoLEP, holmium laser enucleation of the
prostate; PSA, prostate-speciﬁc antigen; RFS, recurrence-free survival.
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normal voiding is regained.3 In this study, however, the
HoLEP þ HIFU procedure never required cystostomy. The combi-
nation of HoLEP before HIFU had more advantages. HoLEP allows
removal of calciﬁcations of the transitional zone that would
otherwise preclude HIFU treatment. It also facilitates treatment of
enlarged prostates by reducing the anterioreposterior diameter
and allowing complete treatment of the peripheral zone with HIFU
in a single session. In the case of TURP, while we must consider the
certain frequency of post-TURP bleeding, it is clear that HoLEP has a
lower frequency of postoperative bleeding.16
In this study, the 5-year PSA biochemical RFS rates according to
the Phoenix ASTRO deﬁnition in the HIFU and HoLEPþHIFU groups
were 57.2% and 67.5%, respectively, with no statistically signiﬁcant
differences. Previously, it was reported that the overall 5-year PSA
biochemical RFS rate of HIFU according to the Phoenix deﬁnition
was 21.2%.11,13 Because of the small sample size, we could not es-
timate the exact and appropriate oncological effects of the
HoLEP þ HIFU treatment. Our study results are clearly superior to
previous reports in terms of the PSA biochemical RFS rate (Fig. 2
and Table 2). We therefore consider that our study results
revealed equal and effective oncological outcomes for HIFU mon-
otherapy and HoLEP þ HIFU therapy. To our knowledge, this is the
ﬁrst report to indicate the efﬁcacy of HoLEP followed by HIFU.Table 2
The prostate-speciﬁc antigen biochemical recurrence-free rates according to
D'Amico et al's9 risk classiﬁcations.
Low Intermediate High
HIFU 6/13 (46.2) 7/11 (63.6) 6/6 (100.0)
HoLEP þ HIFU 1/1 (100.0) 3/5 (60.0) 3/4 (75.0)
P 0.299 0.889 0.197
Data are presented as n/N (%).
HIFU, high-intensity focused ultrasound; HoLEP, holmium laser enucleation of the
prostate.Our methods do have some serious disadvantages. Patients
experienced two hospital admissions to undergo HoLEP and HIFU
on separate occasions. It would clearly be preferable to decrease the
number of operations. Previous paper reported that TURP and HIFU
treatments were performed under the same spinal anesthesia.3 We
also hope to perform HIFU immediately after HoLEP during a single
operation in the future. A second disadvantage is the oncological
outcome. We have not conﬁrmed the real effect of HoLEP on CaP.
Declines in serum PSA are well-known to occur after HoLEP and
TURP. Tinmouth et al17 concluded that the HoLEP procedure causes
a signiﬁcant diminution in PSA that correlates well with the weight
of resected adenoma. Elmansy et al18 retrospectively reviewed data
from 335 menwho underwent HoLEP; the mean PSA dropped from
5.44 ng/mL to 0.91 ng/mL after surgery (P < 0.001). Therefore, we
consider that the PSA decline in this study may not be due to HIFU,
but rather due to HoLEP. However, Koguchi et al19 reported a case of
dissemination of CaP after HoLEP in an 80-year-old patient. More
precise analyses of oncological effects, including longitudinal PSA
data, are thus required.
This study had some limitations. First, this was not a random-
ized trial and the follow-up was admittedly short. Second, no pa-
tient received a prostate biopsy after HIFU in this study. We
therefore have no pathological data to establish pathological
recurrence. As HIFU is a minimally invasive surgery, it seems like a
contradiction to evaluate its efﬁcacy by using prostate biopsywith aTable 3
Incidence of complications following HIFU after complete follow-up at 5 years.
HIFU HoLEP þ HIFU P
Urinary retention due to urethral stricture 4 (13.3) 0 (0.0) 0.224
Urinary tract infection 3 (10.0) 0 (0.0) 0.299
Bladder stone 1 (3.3) 0 (0.0) 0.559
Urethrorectal ﬁstula 1 (3.3) 0 (0.0) 0.559
Data are presented as n (%).
HIFU, high-intensity focused ultrasound; HoLEP, holmium laser enucleation of the
prostate.
Fig. 3. Uroﬂowmetry scores before and after HIFU. (A) Qmax values before and after HIFU. Although there were no signiﬁcant differences between both groups in Qmax values before
treatment and 5 years after HIFU, the Qmax values at 1 year and 3 years after HIFU in the HoLEP þ HIFU group were signiﬁcant higher than those in the HIFU monotherapy group. (B)
Qave values before and after HIFU. Although there were no signiﬁcant differences between both groups in Qave values before treatment and 1 year after HIFU, the Qave values at 3
years and 5 years after HIFU in the HoLEP þ HIFU group were signiﬁcantly higher than those in the HIFU monotherapy group. a) P < 0.05. HIFU, high-intensity focused ultrasound;
HoLEP, holmium laser enucleation of the prostate.
Horiuchi et al / HoLEP and HIFU for CaP 53maximally invasive technique. In addition, we could not evaluate
the cost-effectiveness of adding HoLEP to HIFU. The costebeneﬁt
performance should be analyzed in the future.
In conclusion, HoLEP þ HIFU can be considered as a feasible and
minimally invasive therapy for localized CaP. Pre-HIFU HoLEP could
decrease the duration of indwelling catheterization after HIFU. As a
result, it may also be able to decrease the frequency of urethral
stricture and UTI. HoLEP þ HIFU was equivalent to HIFU mono-
therapy with respect to the 5-year efﬁcacy of cancer control. We are
still collecting data on more patients to evaluate long-term efﬁcacy.Conﬂicts of interest
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